SR3 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Broad Revenue GrowthQ2 sales more than doubled and growth appeared across China, APAC, the Americas and EMEA ex-Middle East. Broad geographic traction, alongside reported China share gains, supports a stronger demand base and reduces reliance on a single regional growth engine over the next several quarters.
Strong Balance SheetGross margin stayed above 74% while cash rose to $181.5M and debt was zero. This combination gives STAAR financial capacity to fund product development, manufacturing transition and commercialization, while limiting refinancing pressure as the business scales.
Established ICL PlatformSTAAR has sold more than 4 million lenses in 85 countries and cites 32 years of Collamer clinical history. That installed experience and broad distribution footprint can support surgeon adoption, market access and continued expansion of the ICL platform.
Bears Say
Weak Cash ConversionDespite the latest rebound, TTM operating and free cash flow are negative, following inconsistent recent periods. If sustained, weak cash conversion could require the balance sheet to fund operations and investment, limiting flexibility even while reported revenue grows.
Product Supply ConstraintsEVO Plus demand exceeded supply and backorders appeared in China, the U.S. and other markets. Persistent capacity constraints could defer sales, frustrate surgeon and customer relationships, and limit the company’s ability to convert strong product demand into dependable revenue.
Tariff-Related Margin PressureTariffs on U.S.-made products shipped to China reduced gross margin, and management expects pressure until all China-bound production is Swiss-made by end-2026. The transition leaves a multi-quarter risk to margins and earnings while manufacturing is relocated.
Staar Surgical News
SR3 FAQ
What was Staar Surgical’s price range in the past 12 months?
Currently, no data Available
What is Staar Surgical’s market cap?
Staar Surgical’s market cap is CHF936.62M.
When is Staar Surgical’s upcoming earnings report date?
Staar Surgical’s upcoming earnings report date is Nov 04, 2026 which is in 29 days.
How were Staar Surgical’s earnings last quarter?
Staar Surgical released its earnings results on Aug 12, 2026. The company reported CHF0.133 earnings per share for the quarter, missing the consensus estimate of CHF0.184 by -CHF0.051.
Is Staar Surgical overvalued?
According to Wall Street analysts Staar Surgical’s price is currently Undervalued.
Does Staar Surgical pay dividends?
Staar Surgical does not currently pay dividends.
What is Staar Surgical’s EPS estimate?
Staar Surgical’s EPS estimate is 0.04.
How many shares outstanding does Staar Surgical have?
Staar Surgical has 50,143,986 shares outstanding.
What happened to Staar Surgical’s price movement after its last earnings report?
Staar Surgical reported an EPS of CHF0.133 in its last earnings report, missing expectations of CHF0.184. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Staar Surgical?
Currently, no hedge funds are holding shares in CH:SR3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Staar Surgical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF24.26 (― Upside)
CHF24.26 (― Upside)
Blogger Sentiment
Bullish
CH:SR3 Sentiment 83%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
8.55%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Staar Surgical
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.
SR3 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted a strong operational and financial recovery: record first-half revenue, significant YoY top-line growth (Q2 net sales +111%), return to profitability (net income $8.1M; adjusted EBITDA $20M), improved cash balance and strategic progress on product launches (EVO Plus) and ERP deployment. Key risks remain—supply constraints (EVO Plus demand outstripping capacity), tariff-related margin pressure until Swiss manufacturing is fully ramped, regional seasonality and market variability (China seasonality, EMEA/Middle East impacts), and near-term ERP and transition costs. On balance the positive financial turnaround, market share gains in China, and clear roadmap for innovation outweigh the operational headwinds.View all CH:SR3 earnings summaries









